Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
Mittal will be driving expansion of the provider network across India
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Site Enhances New Modality CRDMO Platform Capacity for Customers
The AICVD tool can predict the risk of cardiovascular disease.
Govt committed to supporting pharma companies with industry-friendly policies
Subscribe To Our Newsletter & Stay Updated
